Curis, P&G deal

PG received an exclusive worldwide license to use CRIS's Hedgehog agonist technology to develop topical treatments for hair growth. CRIS has an option to co-develop an undisclosed preclinical candidate through Phase II trials. CRIS retains rights to veterinary, local cardiovascular and ex vivo uses of the technology. ...